MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

MDT

83.87

+0.59%↑

VEEV

220.35

+2.08%↑

A

105.08

+2.22%↑

WBA

10.98

0%↓

CHE

587.63

+1.41%↑

Search

Avidity Biosciences Inc

Suletud

SektorTervishoid

30.68 4.64

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

29.89

Max

31.55

Põhinäitajad

By Trading Economics

Sissetulek

-22M

-102M

Müük

637K

3M

Aktsiakasum

-0.8

Kasumimarginaal

-3,439.522

Töötajad

391

EBITDA

-23M

-120M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+137.83% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-214M

3.4B

Eelmine avamishind

26.04

Eelmine sulgemishind

30.68

Uudiste sentiment

By Acuity

40%

60%

143 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Avidity Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. apr 2025, 09:30 UTC

Peamised uudised

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Avidity Biosciences Inc Prognoos

Hinnasiht

By TipRanks

137.83% tõus

12 kuu keskmine prognoos

Keskmine 67.83 USD  137.83%

Kõrge 96 USD

Madal 48 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Avidity Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

12

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

25.8 / N/AToetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

143 / 382 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.